Home
Conditions
Lymphoma, Non-Hodgkin

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,774 public trials 698 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Active, Not Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Active, Not Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Conditions: DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, +21 more
Locations: Loma Linda University Cancer Center Loma Linda, California, United States

Cedars-Sinai Medical Center Los Angeles, California, United States

Advent Health Orlando Orlando, Florida, United States

Indiana University Indianapolis, Indiana, United States

View all 16 locations

View Trial Details

Active, Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

NCT03474744

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I Vienna, Austria

St. Josef-Hospital, Medizinische Klinik I Bochum, Germany

Johanniter GmbH, Johanniter-Krankenhaus Bonn, Germany

ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing Dingolfing, Germany

View all 18 locations

View Trial Details

Active, Not Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt Lymphoma, +23 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Active, Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Augusta-Kranken-Anstalt gGmbH Bochum, Germany

University Hospital Essen Essen, Germany

Universitätsklinikum Freiburg Freiburg im Breisgau, Germany

Universitätsmedizin Georg-August-University Göttingen, Germany

View Trial Details

Active, Not Recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Affiliated Hospital of Hebei University Baoding, China

Beijing Cancer Hospital Beijing, China

Beijing Tongren Hospital, Capital Medical University Beijing, China

Peking University Third Hospital Beijing, China

View all 23 locations

View Trial Details

Active, Not Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

NCT06112847

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: City of Hope Medical Center Duarte, California, United States

City of Hope at Irvine Lennar Irvine, California, United States

View Trial Details

Active, Not Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

NCT04978584

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

NCT05429268

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Medical University Plovdiv Plovdiv, Bulgaria

Acibadem Cityclinica Mhat Tokuda Sofia, Bulgaria

Umhat Alexandrovska Sofia Sofia, Bulgaria

Umhat Sv. Ivan Rilski Ead Sofia, Bulgaria

View all 61 locations

View Trial Details

Active, Not Recruiting

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801

Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 10, +55 more
Locations: CCT Research - Gilbert Neurology Partners Gilbert, Arizona, United States

Barrow Neurological Institute Phoenix, Arizona, United States

CCT Research - Foothills Research Center Phoenix, Arizona, United States

Banner Sun Health Research Institute Sun City, Arizona, United States

View all 68 locations

View Trial Details

Lymphoma, Non-Hodgkin

Lymphoma, Non-Hodgkin trial results

Related conditions